Subtotal $0.00
Shop Now
Ozempic blindness refers to reports linking semaglutide (Ozempic, Wegovy, Rybelsus) to NAION, a rare optic nerve condition that causes sudden, painless vision loss, usually in one eye. Several observational studies have found a higher relative risk in people taking semaglutide, and in June 2025 the European Medicines Agency’s safety committee concluded that NAION is a very rare side effect, affecting up to 1 in 10,000 people. The absolute risk is low, causation is still debated, and the U.S. labels current in October 2026 do not mention NAION. Separately, the Ozempic label warns about diabetic retinopathy complications. Any sudden loss or rapid worsening of vision needs same-day emergency care.
Peptide Labs does not sell Ozempic, Wegovy, Rybelsus or any prescription drug. This article summarizes FDA labels, regulator reviews and published studies. For other effects in the class, see our guide to GLP-1 medicine side effects.
Key Takeaways
- NAION is a sudden, usually painless loss of vision in one eye caused by poor blood flow to the optic nerve.
- Observational studies report from about 1.3 to more than 4 times the relative risk with semaglutide.
- European regulators list NAION as very rare (up to 1 in 10,000); UK regulators estimate about 1 extra case per 10,000 users a year.
- U.S. Ozempic, Wegovy and Rybelsus labels current in October 2026 do not list NAION.
- The Ozempic label warns that diabetic retinopathy can temporarily worsen when blood sugar improves quickly.
- Sudden blindness, a curtain over vision or rapidly worsening eyesight is an emergency.
What is NAION, and why is it called Ozempic blindness?
Non-arteritic anterior ischemic optic neuropathy (NAION) is often described as a stroke of the optic nerve head. According to the American Academy of Ophthalmology’s EyeWiki, it causes painless vision loss in one eye, often described as blurring or cloudiness, and more than two-thirds of people notice it on waking. It affects roughly 2 to 10 people per 100,000 each year. Recognized risk factors include high blood pressure, diabetes, obstructive sleep apnea and a small, crowded optic disc. EyeWiki states that there is no effective therapy, so some loss is often permanent.
The phrase Ozempic blindness became common after a 2024 study, and searches for NAION Ozempic links followed. Total blindness is unusual: in one long-term study cited by EyeWiki, about half of patients kept 20/30 vision or better, but nearly a quarter were left with severe loss. Note the overlap: many people prescribed semaglutide already have diabetes, high blood pressure or sleep apnea, which makes the research hard to untangle.
What the studies on semaglutide and NAION show
All the evidence so far is observational or comes from trials that were not designed to measure NAION. Observational studies can show an association but cannot prove the drug caused it. The main studies:
| Study | Who | Main finding |
|---|---|---|
| Hathaway 2024, JAMA Ophthalmology | 16,827 patients at one U.S. neuro-ophthalmology service | Higher NAION risk with semaglutide: hazard ratio 4.28 in diabetes, 7.64 in overweight or obesity |
| Cai 2025, JAMA Ophthalmology | 37.1 million people with type 2 diabetes in 14 databases | Modest increase, smaller than first reported; 14.5 cases per 100,000 person-years on semaglutide |
| Hsu 2025, JAMA Ophthalmology | 174,584 semaglutide users in Taiwan and matched controls | About 2 to 2.4 times the risk from year 2 onward; no increase in the first year |
| Natividade 2025 meta-analysis | 78 randomized trials, 73,640 people | No rise in eye disorders overall; NAION odds 3.92 but too few cases for firm conclusions |
| Tesfaye 2026, Diabetes, Obesity and Metabolism | 482,912 matched pairs, GLP-1 drugs vs SGLT2 inhibitors | 85% higher NAION risk with GLP-1 drugs; semaglutide estimate 2.78 times |
The first study came from a single specialist eye center, where referral patterns can inflate risk estimates, and its authors said causality needs further study. The much larger multi-database study found a smaller effect that was not statistically clear under one case definition. In April 2026, Healio reported a U.S. Veterans Affairs analysis in JAMA Ophthalmology that found about 2.3 times the risk compared with SGLT2 inhibitors. The direction of the findings is fairly consistent; the size of the risk is not.
What regulators and labels say about Ozempic eyes
Regulators have taken different positions on Ozempic eyes risks:
- European Union. In June 2025 the EMA’s Pharmacovigilance Risk Assessment Committee concluded that NAION is a very rare side effect of semaglutide, affecting up to 1 in 10,000 people, and asked for Ozempic, Rybelsus and Wegovy product information to be updated. It advised stopping semaglutide if NAION is confirmed.
- United Kingdom. The MHRA’s February 2026 safety update says semaglutide in adults with type 2 diabetes may roughly double the relative risk, about one additional case for every 10,000 people taking it per year. Other GLP-1 medicines were not part of that review.
- United States. The Ozempic injection label (revised May 2026), the Wegovy label (June 2026) and the Ozempic tablets and Rybelsus label (January 2026), the versions on DailyMed on October 1, 2026, contain no mention of NAION or optic neuropathy. Neither does the Zepbound label (August 2026).
No regulator has concluded that tirzepatide (Mounjaro, Zepbound) causes NAION. For drug-by-drug detail, see semaglutide side effects, Wegovy side effects and Zepbound side effects.
Semaglutide vision changes from diabetic retinopathy
A different eye warning is printed on the U.S. Ozempic label. Diabetic retinopathy is damage to the blood vessels of the retina from long-term high blood sugar. In SUSTAIN-6, a two-year trial in 3,297 people with type 2 diabetes and high cardiovascular risk funded by Novo Nordisk, diabetic retinopathy complications occurred in 3.0% on Ozempic versus 1.8% on placebo.
The increase was concentrated in people who already had retinopathy: 8.2% versus 5.2%, compared with 0.7% versus 0.4% in people without a known history. The label explains that rapid improvement in blood sugar has been linked to temporary worsening of diabetic retinopathy, that long-term effects have not been studied, and that people with a history of retinopathy should be monitored. The Wegovy and Zepbound labels carry similar warnings for people with type 2 diabetes. These semaglutide vision risks are why regular diabetic eye exams matter before and during therapy.
Blurred vision can also be a sign of low blood sugar, which the Ozempic Medication Guide lists alongside shakiness, sweating and confusion, mainly a risk with insulin or a sulfonylurea. Headache and vision changes together deserve attention; see our article on headaches on Ozempic for warning signs.
Ozempic blindness symptoms: when to get help
MedlinePlus advises emergency care from a provider experienced with eye emergencies for any of these:
- Partial or complete blindness in one or both eyes, even if it is only temporary.
- Double vision, even if it passes.
- A feeling of a shade or curtain being pulled over your vision.
- Blind spots, halos around lights or areas of distorted vision that appear suddenly.
- Sudden blurred vision with eye pain, especially if the eye is red.
The EMA and MHRA give similar advice for semaglutide users: contact a doctor without delay, or go to urgent eye care, if eyesight is lost suddenly or gets worse quickly. Do not wait to see whether it clears. Tell the eye doctor which medicines you take.
Questions to raise with your prescriber
- Do I have risk factors for NAION, such as a crowded optic disc, sleep apnea or poorly controlled blood pressure?
- Should I have a dilated eye exam before starting, especially if I have diabetic retinopathy?
- How often should my eyes be checked while my blood sugar is improving?
- If I have had NAION in one eye, how do the possible risks compare with the benefits for me?
Do not stop a prescribed medicine on your own because of these reports; talk to your prescriber, who can weigh the small absolute risk against your heart, kidney and blood sugar benefits.
Frequently Asked Questions
Can Ozempic cause blindness?
Studies link semaglutide to a higher relative risk of NAION, an optic nerve condition that can cause permanent vision loss. European regulators call it very rare, up to 1 in 10,000 people.
What is NAION?
Non-arteritic anterior ischemic optic neuropathy is reduced blood flow to the front of the optic nerve. It usually causes sudden, painless vision loss in one eye, often noticed on waking.
Does the U.S. Ozempic label mention NAION?
No. The U.S. Ozempic, Wegovy and Rybelsus labels on DailyMed in October 2026 do not mention NAION. EU and UK regulators added it as a very rare side effect.
What eye warning is on the Ozempic label?
Diabetic retinopathy complications. In SUSTAIN-6 they occurred in 3.0% on Ozempic versus 1.8% on placebo, mostly in people who already had retinopathy.
Does tirzepatide cause NAION?
No regulator has reached that conclusion. The UK review covered semaglutide only and said other GLP-1 medicines were still under review.
What should I do if my vision changes on semaglutide?
Sudden vision loss or rapidly worsening eyesight needs emergency care the same day. Gradual or mild changes should still be reported to your prescriber promptly.
Peptide Labs does not sell GLP-1 medicines or any prescription drug. This article is general information, not medical advice. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you.
Last reviewed October 2026.
Related guides: Semaglutide Side Effects: What the Ozempic, Wegovy and Rybelsus Labels Say, GLP-1 Side Effects: What Every GLP-1 Drug Label Warns About, Ozempic Headache: Label Rates, Causes and Warning Signs.